Sacituzumab (CAS 1796566-95-4) is a humanized IgG1 monoclonal antibody that targets TROP2, a protein found on certain cancer cells. It is used to create antibody-drug conjugates (ADCs), such as sacituzumab govitecan, which is approved for treating triple-negative breast cancer (TNBC).
Key Features:
- Target Specificity: Binds to TROP2 on cancer cells.
- Mechanism of Action: Slows tumor growth and boosts immune system activity against cancer cells.
- Molecular Characteristics: Humanized IgG1 monoclonal antibody.
Applications:
- Cancer Therapy: Treats cancers like TNBC that overexpress TROP2.
- Antibody-Drug Conjugates (ADCs): Delivers targeted therapy to cancer cells.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
